NervGen Pharma Corp. (NGEN:NASDAQ) closed at $1.43 on October 23, 2026, up 0.70% on the day. The stock trades 77.3% below its 52-week high of $6.30 and 3.6% above its 52-week low of $1.38. Over the past year, it lost 48.0%. NervGen Pharma Corp. is part of the Health Care sector.
In 252 trading sessions since October 23, 2025, NGEN closed higher on 117 days (46%). Its best day was November 26, 2025 (+24.68%) and its worst was May 22, 2026 (-43.48%). The stock moved 10% or more in a single session 8 times. It opened at least 5% above the previous day's high 4 times.
NervGen (TSXV: NGEN) (OTCQB: NGENF) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies that enable the nervous system to repair itself in settings of neurotrauma and neurologic disease. The Company is evaluating the clinical efficacy of its first- and potential best-in-class lead candidate, NVG-291, in the Phase 1b/2a CONNECT SCI Study in spinal cord injury.
Find more stocks like NGEN with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.